Clee Medical secures seed funding to advance real-time brain imaging for neurosurgery

Clee Medical, a Swiss neurotechnology startup developing ultra-high-resolution real-time imaging for brain surgery, has closed its seed financing round. The round was led by High-Tech Gründerfonds (HTGF), with participation from Zürcher Kantonalbank (ZKB), Kickfund, FONGIT, and Venture Kick, alongside continued support from existing partner Wyss Geneva.

Many neurosurgical procedures require navigating delicate brain structures with millimetre-level precision, yet anatomical shifts and limited intraoperative visibility can make targeting during surgery challenging. Clee Medical is developing minimally invasive neurotechnology solutions to address this gap.

Founded in October 2024 by Matt Lapinski and Abed Hammoud, the company's flagship Neuro Access platform combines ultra-high-resolution real-time intraoperative Optical Coherence Tomography imaging with advanced navigation capabilities to support precision neurosurgery. The technology is designed to provide real-time imaging inside the brain, helping surgeons navigate complex anatomy with greater confidence and enabling safer access to deep brain targets for more targeted neurotherapies.

Built on years of translational research, the platform is being developed to support applications including functional neurosurgery and neuro-oncology.

With the new financing, Clee Medical plans to expand its development and clinical programs, advance toward its first-in-human clinical study, and accelerate the clinical validation of Neuro Access.

The company's long-term vision is to enable neurosurgeons to operate with enhanced real-time insight, improving safety, efficiency, and patient outcomes in complex brain procedures.

Source: Tech.eu